Eric Jonasch, MD | Authors

Articles

Alternative Sunitinib Scheduling for mRCC

March 28, 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).